- #Keynote 355 pembrolizumab trial#
- #Keynote 355 pembrolizumab plus#
- #Keynote 355 pembrolizumab windows#
#Keynote 355 pembrolizumab windows#
The cookie is a session cookies and is deleted when all the browser windows are closed. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. This cookie is native to PHP applications. The cookie is used to remember the user consent for the cookies under the category "Performance". This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to store the user consent for the cookies in the category "Necessary". This cookie is set by GDPR Cookie Consent plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics". The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting". These cookies do not store any personal information.Ĭookielawinfo-checkbox-advertising-targeting This category only includes cookies that ensures basic functionalities and security features of the website. Necessary cookies are absolutely essential for the website to function properly.
#Keynote 355 pembrolizumab plus#
Part two of KEYNOTE-355 enrolled 847 patients who were randomised to receive Keytruda (200mg intravenously on day one of each 21-day cycle) plus nab-paclitaxel, paclitaxel or gemcitabine/carboplatin at various stages in the 21-day cycle or placebo (normal saline on day one of each 21-day cycle) plus nab-paclitaxel, paclitaxel or gemcitabine/carboplatin at the same points in the cycle. The secondary endpoints include objective response rate (ORR), duration of response (DOR), disease control rate (DCR) and safety. Part two was double-blind, with dual primary endpoints of OS and PFS in all participants and in participants whose tumours expressed PD-L1. Part one of the study was open-label and evaluated the safety and tolerability of Keytruda in combination with chemotherapy in 30 patients.
#Keynote 355 pembrolizumab trial#
KEYNOTE-355 is a randomised, two-part, Phase III trial evaluating Keytruda in combination with one of three different chemotherapies compared with placebo plus one of the three chemotherapy regimens for the treatment of locally recurrent inoperable or mTNBC that has not been previously treated with chemotherapy in the metastatic setting. In addition to KEYNOTE-355, other studies in TNBC are ongoing and include KEYNOTE-242 and KEYNOTE-522.
The Keytruda breast cancer clinical development program encompasses several internal and external collaborative studies. “We look forward to sharing these findings with the medical community at an upcoming congress and discussing them with the US Food and Drug Administration (FDA) and other regulatory authorities.” It is very encouraging that Keytruda in combination with chemotherapy has now demonstrated positive results as both a first-line treatment in the metastatic setting with this trial,” said Dr Roger Perlmutter, President of Merck Research Laboratories. “Triple-negative breast cancer is an aggressive malignancy. The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies. The DMC suggested, and Merck has agreed, that the trial will continue to evaluate the other dual primary endpoint of overall survival (OS). The announcement by Merck is based on an interim analysis conducted by an independent Data Monitoring Committee (DMC), which identified first-line treatment with Keytruda in combination with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabine/carboplatin) demonstrated a statistically significant and clinically meaningful improvement in PFS compared to chemotherapy alone in patients. The trial is testing the anti-PD-1 monoclonal antibody (mAb) therapy in combination with chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC) whose tumours expressed PD-L1. The producers of Keytruda ® (pembrolizumab) have announced that the drug, in combination with chemotherapy, has met its progression-free survival (PFS) primary endpoint in the Phase III KEYNOTE-355 trial.
0 kommentar(er)
